Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective

Daniela Zinzi, Ioanna Vlachaki, Edel Falla, Theo Mantopoulos (Lead / Corresponding author), Dilip Nathwani

    Research output: Contribution to journalArticlepeer-review

    2 Citations (Scopus)
    88 Downloads (Pure)


    Background: Early discharge (ED) from hospital and outpatient parenteral antibiotic therapy (OPAT) are effective approaches for the management of a range of infections, including acute bacterial skin and skin structure infections (ABSSSI). Strategies that facilitate ED, thereby reducing complications such as healthcare-acquired infection whilst enhancing patient quality of life, are being increasingly adopted in line with good antimicrobial stewardship practice. This study presents a cost-minimisation analysis for the use of oritavancin at ED versus relevant comparators from a National Health Service (NHS) and personal and social services United Kingdom perspective.

    Methods: A cost-minimisation model considering adult patients with ABSSSI with suspected or confirmed methicillin-resistant Staphylococcus aureus (MRSA) infection, was developed based on publicly available NHS costs, practice guidelines for ABSSSI and clinical expert's opinion. Cost of treatment and treatment days were compared for oritavancin at ED to dalbavancin, teicoplanin, daptomycin and linezolid.

    Results: Following the empiric use of either flucloxacillin or vancomycin in the inpatient setting, oritavancin was compared to OPAT with dalbavancin, teicoplanin and daptomycin, and oral linezolid from day 4 of treatment. Oritavancin at ED reduced treatment duration by 0.8 days and led to cost savings of £281 in comparison to dalbavancin. In comparison to teicoplanin, daptomycin and linezolid, oritavancin reduced treatment duration by 5 days, with marginally higher costs (£446, £137, and £1,434, respectively).

    Conclusion: Oritavancin, used to support ED, is associated with lower costs compared with dalbavancin and reduced treatment duration relative to all comparators. Its use would support an ED approach in MRSA ABSSSI management.

    Original languageEnglish
    Pages (from-to)1371-1381
    Number of pages11
    JournalEuropean Journal of Health Economics
    Issue number8
    Early online date3 Feb 2022
    Publication statusPublished - Nov 2022


    • Acute bacterial skin and skin structure infections
    • Cost-minimisation analysis
    • Methicillin-resistant Staphylococcus aureus infection
    • Oritavancin
    • United Kingdom

    ASJC Scopus subject areas

    • Economics, Econometrics and Finance (miscellaneous)
    • Health Policy


    Dive into the research topics of 'Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective'. Together they form a unique fingerprint.

    Cite this